Sunshine Biopharma (SBFM)

$1.23 0.00 (N/A)
Market Cap 5.99M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 25,900
Avg Vol 48,328
Day's Range N/A - N/A
Shares Out 4.91M
Stochastic %K 20%
Beta 1.53
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 954 330 0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
Masterrunner
Masterrunner Feb. 4 at 12:20 AM
$SBFM Hey ChatGPT, what could SBFM shareholders realistically get in a buyout? Straight answer — no fluff: If a buyer made an offer today: Most likely range: $1.65–$1.80 per share Upside case: $2.00–$2.20 per share (would require strong strategic interest) Hard floor: ~$1.45 per share Translation: SOLID premium from current levels ✊ So yeah… probably hold off on that yacht deposit for now 😄 PS: Unless they actually do cure cancer
1 · Reply
RonRon1234
RonRon1234 Feb. 3 at 6:55 PM
$SBFM yah, need you to get bought out so I can use the money on other stocks...please and thanks.
0 · Reply
Tryitin
Tryitin Feb. 3 at 1:10 AM
$SBFM Ask price in Charles Schawb is 18 now. Is that normal? Hmm...
2 · Reply
stockanalyzer777
stockanalyzer777 Feb. 3 at 1:05 AM
$SBFM
2 · Reply
contra7
contra7 Feb. 2 at 5:48 PM
$SBFM Dr Steve Slilaty founded Qbiogene/Quantum Biotechnologies in 1991 and built the company from an early stage/start up biotech into a mature revenue producing biotech tools business. The company grew to produce over 6OM in annual revenue before being acquired by MP Biomedicals on 9/27/2004, a private biotech company owned by billionaire Milan Panic for an “undisclosed amount between $10M-$10B”. Private companies do not have to publicly disclose buyout terms.
1 · Reply
contra7
contra7 Jan. 31 at 7:22 PM
$SBFM This company is currently checking all the boxes that imply Sunshine is presently in late stage negotiations as an acquisition target 🎯. Here’s why this is the most plausible scenario: •Both the CEO and CFO have change of control clauses in their contracts that will pay them handsomely in the event of a buyout. IMO this was the plan all along and despite their mismanagement woes they overachieved by acquiring Nora Pharma knowing the combined entity would be very enticing for a large cap biotech. •When companies are undergoing the M&A process the stock price is usually detached from the inherent value of the company. •The abrupt departure of Chamoun and the fact that his replacement has very little pharmaceutical experience and over 20 years of finance and accounting experience, a perfect placeholder during M&A negotiations. •The recent increase in common shares to 680k for the employee incentive program which is very common before M&A closes to ensure employee retention.
3 · Reply
Tryitin
Tryitin Jan. 30 at 8:58 PM
$SBFM 1.16 thru 1.25 is a strong loading zone. However, it needs to stay above 1.16 Mgmt MFKRS do something at least...Its been more than 3 months since we have seen any news PR....WAKE UP...
0 · Reply
MB66
MB66 Jan. 30 at 1:17 PM
$SBFM back to testing those ATL’s again, I see… Come on!! I hate this management…..
1 · Reply
Jahubba
Jahubba Jan. 30 at 3:51 AM
$SBFM My stock app on my phone using yahoo finance shows SBFM with earnings per share of 5.31. If true then price per share should be 150 or more
1 · Reply
RonRon1234
RonRon1234 Jan. 29 at 4:50 PM
$SBFM when was the last time insiders bought this stock?
3 · Reply
Latest News on SBFM
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Oct 28, 2025, 2:10 PM EDT - 3 months ago

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Oct 28, 2025, 7:45 AM EDT - 3 months ago

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Oct 20, 2025, 7:45 AM EDT - 3 months ago

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Oct 16, 2025, 7:45 AM EDT - 3 months ago

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Oct 14, 2025, 10:45 AM EDT - 4 months ago

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Oct 14, 2025, 8:50 AM EDT - 4 months ago

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Oct 9, 2025, 8:00 AM EDT - 4 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 7 months ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 8 months ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 9 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 9 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 10 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 10 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 10 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 11:35 AM EDT - 10 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 11 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 11 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 11 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 1 year ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 3 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 3 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 3 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Nov 16, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Masterrunner
Masterrunner Feb. 4 at 12:20 AM
$SBFM Hey ChatGPT, what could SBFM shareholders realistically get in a buyout? Straight answer — no fluff: If a buyer made an offer today: Most likely range: $1.65–$1.80 per share Upside case: $2.00–$2.20 per share (would require strong strategic interest) Hard floor: ~$1.45 per share Translation: SOLID premium from current levels ✊ So yeah… probably hold off on that yacht deposit for now 😄 PS: Unless they actually do cure cancer
1 · Reply
RonRon1234
RonRon1234 Feb. 3 at 6:55 PM
$SBFM yah, need you to get bought out so I can use the money on other stocks...please and thanks.
0 · Reply
Tryitin
Tryitin Feb. 3 at 1:10 AM
$SBFM Ask price in Charles Schawb is 18 now. Is that normal? Hmm...
2 · Reply
stockanalyzer777
stockanalyzer777 Feb. 3 at 1:05 AM
$SBFM
2 · Reply
contra7
contra7 Feb. 2 at 5:48 PM
$SBFM Dr Steve Slilaty founded Qbiogene/Quantum Biotechnologies in 1991 and built the company from an early stage/start up biotech into a mature revenue producing biotech tools business. The company grew to produce over 6OM in annual revenue before being acquired by MP Biomedicals on 9/27/2004, a private biotech company owned by billionaire Milan Panic for an “undisclosed amount between $10M-$10B”. Private companies do not have to publicly disclose buyout terms.
1 · Reply
contra7
contra7 Jan. 31 at 7:22 PM
$SBFM This company is currently checking all the boxes that imply Sunshine is presently in late stage negotiations as an acquisition target 🎯. Here’s why this is the most plausible scenario: •Both the CEO and CFO have change of control clauses in their contracts that will pay them handsomely in the event of a buyout. IMO this was the plan all along and despite their mismanagement woes they overachieved by acquiring Nora Pharma knowing the combined entity would be very enticing for a large cap biotech. •When companies are undergoing the M&A process the stock price is usually detached from the inherent value of the company. •The abrupt departure of Chamoun and the fact that his replacement has very little pharmaceutical experience and over 20 years of finance and accounting experience, a perfect placeholder during M&A negotiations. •The recent increase in common shares to 680k for the employee incentive program which is very common before M&A closes to ensure employee retention.
3 · Reply
Tryitin
Tryitin Jan. 30 at 8:58 PM
$SBFM 1.16 thru 1.25 is a strong loading zone. However, it needs to stay above 1.16 Mgmt MFKRS do something at least...Its been more than 3 months since we have seen any news PR....WAKE UP...
0 · Reply
MB66
MB66 Jan. 30 at 1:17 PM
$SBFM back to testing those ATL’s again, I see… Come on!! I hate this management…..
1 · Reply
Jahubba
Jahubba Jan. 30 at 3:51 AM
$SBFM My stock app on my phone using yahoo finance shows SBFM with earnings per share of 5.31. If true then price per share should be 150 or more
1 · Reply
RonRon1234
RonRon1234 Jan. 29 at 4:50 PM
$SBFM when was the last time insiders bought this stock?
3 · Reply
djgestates
djgestates Jan. 29 at 12:07 PM
$SBFM To be clear, SBFM was a target, NOT a participant in the scheme.
1 · Reply
djgestates
djgestates Jan. 29 at 11:38 AM
A couple was charge last week for a money laundering scheme which included, among five other companies, Sunshine Biopharma. http://fox5sandiego.com/news/local-news/rosens-indicted-securities-fraud/#:~:text=Prosecutors%20allege%20that%20since%202020,All%20rights%20reserved.$SBFM
2 · Reply
Nuisance
Nuisance Jan. 28 at 7:52 PM
$SBFM rocke
0 · Reply
stockanalyzer777
stockanalyzer777 Jan. 28 at 7:51 PM
$SBFM
0 · Reply
contra7
contra7 Jan. 28 at 7:51 PM
$SBFM
0 · Reply
stockanalyzer777
stockanalyzer777 Jan. 28 at 7:41 PM
$SBFM I am hoping for a PR tomorrow. Tomorrow makes it 3 months exactly since the last PR. I want to see IND/FDA application submitted and the start of human trials
0 · Reply
LH1975New
LH1975New Jan. 28 at 2:23 PM
$SBFM
0 · Reply
Nuisance
Nuisance Jan. 28 at 10:50 AM
$SBFM
0 · Reply
peepthestamp
peepthestamp Jan. 28 at 10:34 AM
$SBFM
0 · Reply
Kalini67
Kalini67 Jan. 28 at 10:30 AM
$SBFM Good morning Sunshine!
0 · Reply
stockanalyzer777
stockanalyzer777 Jan. 28 at 12:31 AM
$SBFM I've been stacking so much cash on slv. Its so predictable and it allows me to trade 24/7. It goes down to $96-97 dollars and shoots up to 102. The cycle keeps repeating. Just wanted to share my trading strategy with you all while waiting for SBFM to do its job.
0 · Reply
Masterrunner
Masterrunner Jan. 27 at 10:29 PM
$SBFM What a day!
3 · Reply